Wedbush Reiterates Outperform Rating for Aprea Therapeutics (NASDAQ:APRE)

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “outperform” rating reiterated by equities research analysts at Wedbush in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $7.00 target price on the stock.

A number of other research firms have also recently commented on APRE. HC Wainwright dropped their price target on shares of Aprea Therapeutics from $4.00 to $1.20 and set a “buy” rating for the company in a research note on Tuesday. Zacks Research raised Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.10.

Aprea Therapeutics Stock Up 0.7%

APRE traded up $0.01 during trading on Tuesday, reaching $0.74. The company had a trading volume of 150,600 shares, compared to its average volume of 2,300,393. The business has a 50 day simple moving average of $0.76 and a 200-day simple moving average of $1.05. The stock has a market cap of $8.52 million, a P/E ratio of -0.38 and a beta of 1.42. Aprea Therapeutics has a 52 week low of $0.55 and a 52 week high of $2.30.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Monday, March 16th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.06. Aprea Therapeutics had a negative net margin of 4,405.59% and a negative return on equity of 96.33%. The business had revenue of $0.00 million for the quarter. As a group, equities research analysts expect that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned 0.67% of Aprea Therapeutics at the end of the most recent reporting period. 34.19% of the stock is owned by institutional investors and hedge funds.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.